About Molcure
Molcure is a company based in Tokyo (Japan) founded in 2013 by Yutaro Kyono and Ryu Ogawa. Molcure has raised $11.73 million across 5 funding rounds from investors including Dai-Ichi Life, Nippon ChemiPhar and JAFCO Group. Molcure operates in a competitive market with competitors including Biological Dynamics, Depixus, Genomics, Seven Bridges Genomics and Oxford Immunotec, among others.
- Headquarter Tokyo, Japan
- Founders Yutaro Kyono, Ryu Ogawa
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.73 M (USD)
in 5 rounds
-
Latest Funding Round
$7.2 M (USD), Series C
Aug 18, 2021
-
Investors
Dai-Ichi Life
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Molcure
Unlock access to complete
Unlock access to complete
Funding Insights of Molcure
Molcure has successfully raised a total of $11.73M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $7.2 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Molcure
Molcure has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Dai-Ichi Life, Nippon ChemiPhar and JAFCO Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital support is provided to seed and early-stage startups.
|
Locked | Locked | Locked | |
|
Private equity investment firm backed by Japan Post Group
|
Locked | Locked | Locked | |
|
Early-stage tech ventures in the US and Asia are funded.
|
Locked | Locked | Locked |
Investor details for Molcure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Molcure
Investment portfolio details for Molcure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Molcure
Detailed financials for Molcure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Molcure Comparisons
Peer comparison for Molcure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Molcure
Molcure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological Dynamics, Depixus, Genomics, Seven Bridges Genomics and Oxford Immunotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Proprietary lab-on-chip platform for nanoparticle isolation is offered.
|
|
| Locked | Locked | Locked |
Single-molecule genetic and epigenetic sequencing solutions are provided.
|
|
| Locked | Locked | Locked |
Genomic risk assessment and prevention platform is provided.
|
|
| Locked | Locked | Locked |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| Locked | Locked | Locked |
Immune markers are utilized by Oxford Immunotec for disease diagnostics.
|
|
| Locked | Locked | Locked |
Bioinformatics tools are provided for analyzing microbial genomic sequencing data.
|
Detailed competitors of Molcure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Molcure
Complete news archive for Molcure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Molcure
Molcure was founded in 2013.
Molcure is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Ryu Ogawa is the current CEO of Molcure. They have also founded this company.
Molcure is a funded company, having raised a total of $11.73M across 5 funding rounds to date.
The company was founded in 2013 in Tokyo, Japan, within the biotechnology sector. An AI-driven platform is offered for drug discovery and molecular design. Next-generation sequencing and molecular biology techniques are employed to identify and detect antibody molecules. Core operations center on accelerating therapeutic development through data-driven approaches in the pharmaceutical industry.
Molcure's top competitors include Depixus, Ingenuity Systems and Phoremost.
Molcure has 8 investors. Key investors include Dai-Ichi Life, Nippon ChemiPhar, JAFCO Group, STRIVE, and Japan Post Capital.